---
layout: default
title: Nitrous Oxide
parent: 僅模型預測 (L5)
nav_order: 253
evidence_level: L5
indication_count: 1
---

# Nitrous Oxide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Nitrous Oxide: From Procedural Analgesia to Benign Prostatic Hyperplasia

## One-Sentence Summary

Nitrous oxide (N₂O, "laughing gas") is a well-established inhaled anesthetic and analgesic agent widely used for procedural sedation and pain management.
The TxGNN model predicts it may be effective for **Benign Prostatic Hyperplasia (BPH)**, with a prediction score of **99.52%**.
However, the supporting evidence is critically weak — **1 clinical trial** found is about procedural sedation during prostate biopsy (not BPH treatment), and **3 publications** all relate to anesthesia in urological settings rather than BPH pharmacotherapy. This prediction is assessed as **model artifact** rather than a genuine therapeutic signal.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Inhaled procedural analgesia/anesthesia (no formal Philippines registration) |
| Predicted New Indication | Benign Prostatic Hyperplasia (BPH) |
| TxGNN Prediction Score | 99.52% |
| Evidence Level | L5 — Model prediction only; no supporting therapeutic studies |
| Philippines Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known pharmacology, nitrous oxide acts primarily on **NMDA receptors** and **opioid receptors**, producing analgesia and anxiolysis via inhalational delivery. It has no established pharmacological target relevant to BPH pathophysiology.

BPH is treated via two main mechanisms: **α₁-adrenergic receptor blockade** (e.g., tamsulosin), which relaxes prostatic smooth muscle tone, or **5α-reductase inhibition** (e.g., finasteride), which reduces dihydrotestosterone (DHT)-driven prostate volume growth. Nitrous oxide has no known activity on either pathway, and does not affect prostatic smooth muscle tension, prostate volume, or DHT synthesis.

A critical confound must be flagged: the TxGNN model may be conflating **Nitrous oxide (N₂O, laughing gas)** with **Nitric oxide (NO, nitrogen monoxide)**. Nitric oxide — an entirely distinct compound — does have smooth muscle relaxation effects relevant to lower urinary tract physiology and has been studied in BPH contexts. The high TxGNN score (0.9952) most likely reflects a **co-occurrence bias** in training data, where N₂O appears frequently alongside urological procedures (e.g., prostate biopsies), rather than any true disease-modifying relationship with BPH. This prediction is not considered mechanistically plausible.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT05803096](https://clinicaltrials.gov/study/NCT05803096) | Phase 4 | Completed | 143 | Self-administered N₂O during transrectal prostate biopsy to reduce anxiety and pain — **procedural sedation only, no BPH treatment endpoints** |

> ⚠️ **Note:** The only identified trial evaluates N₂O as an anxiolytic/analgesic adjunct during prostate biopsy, not as a treatment for BPH. No endpoints relevant to BPH (IPSS score, urinary flow rate, prostate volume, PSA) were studied. This trial provides **zero evidence** for N₂O as a BPH therapy.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [4171323](https://pubmed.ncbi.nlm.nih.gov/4171323/) | 1968 | Technical Report | International Surgery | Equipment description for cryotherapy of prostate obstruction — N₂O used as cryogen, not pharmacotherapy |
| [4108916](https://pubmed.ncbi.nlm.nih.gov/4108916/) | 1971 | Case Series | Zeitschrift für Anasthesie | Combination anesthesia with methohexital in high-risk urological patients — anesthetic management, not BPH treatment |
| [9223887](https://pubmed.ncbi.nlm.nih.gov/9223887/) | 1997 | Case Report | Masui (Japanese Journal of Anesthesiology) | Anesthetic management for suprapubic prostatectomy in a patient with pure autonomic failure — anesthesia context only |

> ⚠️ **Note:** All three publications address anesthetic or procedural use of N₂O in urological settings. None study N₂O as a therapeutic agent for BPH. These publications do not constitute evidence for drug repurposing.

---

## Philippines Market Information

Nitrous oxide has **no registered pharmaceutical products** in the Philippines (FDA Philippines). No authorization records are available.

---

## Safety Considerations

Please refer to the package insert for safety information. No Philippines-specific label warnings, contraindications, or drug interaction data were available in this evidence pack.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN prediction score is high (99.52%), but all available evidence indicates this is a **model artifact driven by co-occurrence bias** — N₂O co-appears with prostate-related procedures in training data without any pharmacological relevance to BPH. There is no mechanistic plausibility, no BPH-directed clinical trial evidence, and no supporting literature. Additionally, the model may be conflating nitrous oxide (N₂O) with nitric oxide (NO), which are chemically and pharmacologically distinct compounds.

**To proceed, the following would be needed:**
- Clarification of whether TxGNN's prediction is indeed for N₂O (DB06690) versus NO — review the knowledge graph node assignment
- A mechanistic hypothesis explaining how NMDA receptor antagonism or opioid receptor modulation could improve BPH symptoms or progression
- At minimum one preclinical study (in vitro or animal model) demonstrating N₂O activity on prostatic smooth muscle, 5α-reductase, or relevant lower urinary tract biomarkers
- Given the absence of Philippines registration, regulatory pathway assessment would also be required before any clinical development
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

